Metabolic syndrome: an update on diagnostic criteria, pathogenesis, and genetic links

Hormones

Volumn 17, Issue 3, 2018, Pages 299-313

  Zafar, Uzma ^a,b   Khaliq, Saba ^a   Ahmad, Hafiz Usman ^a   Manzoor, Sobia ^c   Lone, Khalid P ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b Lahore Medical and Dental College ^*  (Pakistan)

^c NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

Central obesity; Cytokines; Insulin resistance; Metabolic syndrome; Single nucleotide polymorphisms

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BETA 3 ADRENERGIC RECEPTOR; FERRITIN; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN SENSITIZING AGENT; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; URIC ACID;

ADIPOCYTE; ADIPOSE TISSUE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DISEASE EXACERBATION; FATTY ACID BLOOD LEVEL; FATTY LIVER; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; GENETIC VARIATION; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIPID HOMEOSTASIS; LIPOTOXICITY; MAJOR ADVERSE CARDIAC EVENT; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; GENETICS; IMMUNOLOGY; METABOLISM; OBESITY;

HUMANS; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME; OBESITY;

EID: 85052990700     PISSN: 11093099     EISSN: 25208721     Source Type: Journal    
DOI: 10.1007/s42000-018-0051-3     Document Type: Review

References (164)

1. Weiss R, Bremer AA, Lustig RH (2013) What is metabolic syndrome, and why are children getting it? Ann N Y Acad Sci 1281:123–140
2. Alberti KG, Zimmet P, Shaw J (2005) IDF epidemiology task force consensus group. The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062
3. Grundy SM (2008) Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 28:629–663
4. Uzunlulu M, Telci Caklili O, Oguz A (2016) Association between metabolic syndrome and cancer. Ann Nutr Metab 68:173–179
5. Kylin E (1923) Studien ueber das Hypertonie-Hyperglyca “mie-Hyperurika” miesyndrom. Zentralblatt fuer Innere Medizin 44:105–127
6. Vague J (1947) Sexual differentiation. A factor affecting the forms of obesity. Presse Med 30:S39–S40
7. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1595–1607
8. Kaur J (2014) A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014:943162
9. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ (2015) Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA 313:1973–1974
10. O'Neill S, O'Driscol L (2015) Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev 16:1–12
11. Pucci G, Alcidi R, Tap L, Battista F, Mattace-Raso F, Schillaci Pucci G (2017) Sex and gender related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: a review of the literature. Pharmacol Res 120:34–42
12. Kuk JL, Ardern CI (2010) Age and sex differences in the clustering of metabolic syndrome factors: association with mortality risk. Diabetes Care 33:2457–2461
13. Beltrán-Sánchez H, Harhay MO (2013) Prevalence and trends of metabolic syndrome in the adult US population, 1999–2010. J Am Coll Cardiol 62:697–703
14. Ali NS, Khuwaja AK, Adnan-ur-Rehman, Nauji K (2012) Retrospective analysis of metabolic syndrome: prevalence and distribution in executive population in urban Pakistan. Int J Family Med 2012:649383
15. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23:469–480
16. Basit A, Shera AS (2008) Prevalence of metabolic syndrome in Pakistan. Metab Syndr Relat Disord 6:15–17
17. Hydrie MZ, Shera AS, Fawwad A, Basit A, Hussain A (2009) Prevalence of metabolic syndrome in urban Pakistan (Karachi): comparison of newly proposed International Diabetes Federation and modified Adult Treatment Panel III criteria. Metab Syndr Relat Disord 7:119–124
18. Wen J, Yang J, Shi Y (2015) Comparisons of different metabolic syndrome definitions and associations with coronary heart disease, stroke, and peripheral arterial disease in a rural Chinese population. PLoS One 10:e0126832
19. Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645
20. Kassi E, Pervanidou P, Kaltsas G, Chrousos G (2011) Metabolic syndrome: definitions and controversies. BMC Med 9:48
21. Ahmed A, Khan T, Yasmeen T, Awan S, Islam N (2012) Metabolic syndrome in type 2 diabetes: comparison of WHO, modified ATPIII & IDF criteria. J Pak Med Assoc 62:569–574
22. Ford ES (2005) Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28:2745–2749
23. Wisse BE (2004) The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 15:2792–2800
24. Buse JB, Polonsky KS, Burant CF (2003) Type 2 diabetes mellitus. In: Laren PR, Kronenberg HM, Melmed S, Polonsky KS (eds) Williams text book of endocrinology. Saunders, Philadelphia, pp 1427–1442
25. Boucher J, Kleinridders A, Kahn CR (2014) Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol 6:a009191. 10.1101/cshperspect.a009191
26. Fröjdö S, Vidal H, Pirola L (2009) Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans. Biochim Biophys Acta 1792:83–92
27. Ijuin T, Takenawa T (2012) Regulation of insulin signaling by the phosphatidylinositol 3, 4, 5-triphosphate phosphatase SKIP through the scaffolding function of Pak1. J Mol Cell Biol 32:3570–3584
28. Jason S, Cui W (2016) Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signaling in pluripotency and cell fate determination. Development 143:3050–3060
29. Draznin B (2010) Mitogenic action of insulin: friend foe or “frenemy”? Diabetologia 53:229–233
30. Schulman IH, Zhou MS (2009) Vascular insulin resistance: a potential link between cardiovascular and metabolic diseases. Curr Hypertens Rep 11:48–55
31. Zhou M-S, Wang A, Yu H (2014) Link between insulin resistance and hypertension: what is the evidence from evolutionary biology? Diabetol Metab Syndr 6:12
32. Brown MS, Goldstein JL (2008) Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7:95–96
33. Wilcox G (2005) Insulin and insulin resistance. Clin Biochem Rev 26:19
34. Shah A, Mehta N, Reilly MP (2008) Adipose inflammation, insulin resistance, and cardiovascular disease. J Parenter Enter Nutr 32:638–644
35. Montgomery MK, Turner N (2015) Mitochondrial dysfunction and insulin resistance: an update. Endocr Connect 4:R1–R15
36. Naimi M, Gautier N, Chaussade C, Valverde AM, Accili D, Van Obberghen E (2007) Nuclear forkhead box O1 controls and integrates key signaling pathways in hepatocytes. Endocrinology 148:2424–2434
37. Ginsberg HN, Zhang YL, Hernandez-Ono A (2005) Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 36:232–240
38. Gastaldelli A, Gaggini M, DeFronzo RA (2017) Role of adipose tissue insulin resistance in the natural history of type 2 diabetes: results from the San Antonio metabolism study. Diabetes 66:815–822
39. Consitt LA, Bell JA, Houmard JA (2009) Intramuscular lipid metabolism, insulin action, and obesity. IUBMB Life 61:47–55
40. Martins AR, Nachbar RT, Gorjao R (2012) Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids Health Dis 11:30
41. DeFronzo RA, Tripathy D (2009) Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32:S157–S163
42. Petersen KF, Dufour S, Savage DB et al (2007) The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 104:12587–12594
43. Kumar A, Tewari P, Sahoo SS, Srivastava AK (2005) Prevalence of insulin resistance in first degree relatives of type-2 diabetes mellitus patients: a prospective study in North Indian population. Indian J Clin Biochem 20:10–17
44. Buchanan TA (2007) Perspectives in diabetes. How can we prevent type 2 diabetes? Diabetes 56:1502–1507
45. Cornier M-A, Dabelea D, Hernandez TL (2008) The metabolic syndrome. Endocr Rev 29:777–822
46. Gustafson B, Hammarstedt A, Andersson CX, Smith U (2007) Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 27:2276–2283
47. Heilbronn LK, Campbell LV (2008) Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 14:1225–1230
48. Castouldi A, de Souza CN, Camara NOS, Moraes-Vieira VM (2015) The macrophage switch in obesity development. Front Immunol 6:637
49. Usman S, Jafri SA (2014) Insulin resistance study in diabetes mellitus type II and its correlation with obesity. Am J Life Sci 2:96–102
50. Abu-Farha M, Behbehani MK, Elkum N (2014) Comprehensive analysis of circulating adipokines and hsCRP association with cardiovascular disease risk factors and metabolic syndrome in Arabs. Cardiovasc Diabetol 13:76
51. Gnacinska M, Małgorzewicz S, Stojek M, Lysiak-Szydłowska W, Sworczak K (2009) Role of adipokines in complications related to obesity: a review. Adv Med Sci 54:150–157
52. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332–339
53. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784–1792
54. Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB (2006) Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator activated receptor alpha. Diabetes 55:2562–2570
55. Chandran M, Phillips SA, Ciaraldi T, Henry RR (2003) Adiponectin: more than just another fat cell hormone? Diabetes Care 26:2442–2450
56. Okamoto Y, Arita Y, Nishida M et al (2000) An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32:47–50
57. Valsamakis G, Chetty R, McTernan PG, Al-Daghri NM, Barnett AH, Kumar S (2003) Fasting serum adiponectin concentration is reduced in Indo-Asian subjects and is related to HDL cholesterol. Diabetes Obes Metab 5:131–135
58. Fisman EZ, Tenenbaum A (2014) Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol 13:103
59. Swarbrick MM, Havel PJ (2008) Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 6:87–102
60. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I (2004) Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29–33
61. Kim JY, Ahn SV, Yoon JH et al (2013) Prospective study of serum adiponectin and incident metabolic syndrome. Diabetes Care 36:1547–1553
62. Mohammadi M, Gozashti MH, Aghadavood M, Mehdizadeh MR, Hayatbakhsh MM (2017) Clinical significance of serum IL-6 and TNF-α levels in patients with metabolic syndrome. Rep Biochem Mol Biol 6:74–79
63. Sedger LM, McDermott MF (2014) TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants—past, present and future. Cytokine Growth Factor Rev 25:453–472
64. Dalziel B, Gosby AK, Richman RM, Bryson JM, Caterson ID (2002) Association of the TNF -308 G/A promoter polymorphism with insulin resistance in obesity. Obes Res 10:401–407
65. Navarro-González JF, Mora-Fernández C (2008) The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19:433–442
66. Vikram NK, Bhatt SP, Bhushan B (2011) Associations of -308G/A polymorphism of tumor necrosis factor (TNF)-α gene and serum TNF-α levels with measures of obesity, intra-abdominal and subcutaneous abdominal fat, subclinical inflammation and insulin resistance in Asian Indians in North India. Dis Markers 31:39–46
67. Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM (2006) Tumor necrosis factor alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res 99:69–77
68. Kim JH, Bachmann RA, Chen J (2009) Interleukin-6 and insulin resistance. Vitam Horm 80:613–633
69. Bastard J-P, Maachi M, Lagathu C et al (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17:4–12
70. Senn JJ, Klover PJ, Nowak IA, Mooney RA (2005) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3399
71. Antuna-Puente B, Feve B, Fellahi S, Bastard J-P (2008) Adipokines: the missing link between insulin resistance and obesity. Diabete Metab 34:2–11
72. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745–E751
73. Garg PK, Biggs ML, Carnethon M et al (2014) Metabolic syndrome and risk of incident peripheral artery disease: the cardiovascular health study. Hypertension 63:413–419
74. Mottillo S, Filion KB, Genest J et al (2010) The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56:1113–1132
75. Kahn RBJ, Ferrannini E, Stern M et al (2005) American Diabetes Association; European Association for the study of diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European association for the study of diabetes. Diabetes Care 28:2289–2304
76. Jurimae J, Gruodyte R, Saar M et al (2011) Plasma visfatin and adiponectin concentrations in physically active adolescent girls: relationships with insulin sensitivity and body composition variables. J Pediatr Endocrinol Metab 24:419–425
77. Rhie YJ, Choi BM, Eun SH et al (2011) Association of serum retinol binding protein 4 with adiposity and pubertal development in Korean children and adolescents. J Korean Med Sci 26:797–802
78. Janssen I, Katzmarzyk PT, Srinivasan SR et al (2005) Combined influence of body mass index and waist circumference on coronary artery disease risk factors among children and adolescents. Pediatrics 115:1623–1630
79. Urbina EM, Khoury PR, McCoy CE et al (2013) Triglyceride to HDL-c ratio and increased arterial stiffness in children, adolescents, and young adults. Pediatrics 131:e1082–e1090
80. Burns SF, Lee SJ, Arslanian SA (2012) Surrogate lipid markers for small dense low-density lipoprotein particles in overweight youth. J Pediatr 161:991–996
81. Sassoon DJ, Goodwill AG, Noblet JN et al (2016) Obesity alters molecular and functional cardiac responses to ischemia/reperfusion and glucagon-like peptide-1 receptor agonism. Basic Res Cardiol 111:43
82. Dincer UD (2012) Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy? Diabetes Metab Syndr Obes 5:89–99
83. Okatan EN, Durak AT, Turan B (2016) Electrophysiological basis of metabolic-syndrome-induced cardiac dysfunction. Can J Physiol Pharmacol 94:1064–1073
84. Santulli G, Pagano G, Sardu C et al (2015) Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J Clin Invest 125:1968–1978
85. Lavorato M, Huang TQ, Iyer VR et al (2015) Dyad content is reduced in cardiac myocytes of mice with impaired calmodulin regulation of RyR2. J Muscle Res Cell Motil 36:205–214
86. Engin AB (2017) What is lipotoxicity? Adv Exp Med Biol 960:197–220
87. Kahn SE, Prigeon RL, Schwartz RS et al (2001) Obesity, body fat distribution, insulin sensitivity and islet beta-cell function as explanations for metabolic diversity. J Nutr 131:354S–360S
88. Berg AH, Scherer PE (2005) Adipose tissue inflammation and cardiovascular disease. Circ Res 90:939–949
89. Lelliot C, Vidal Puig AJ (2004) Lipotoxicity, an imbalance between lipogenesis de novo and fatty acid oxidation. Int J Obes Relat Metab Disord 28:S22–S28
90. Schaffer JE (2016) Lipotoxicity: many roads to cell dysfunction and cell death: introduction to a thematic review series. J Lipid Res 57:1327–1328
91. Estadella D, da Penha Oller do Nascimento CM, Oyama LM, Ribeiro EB, Damaso AR, de Piano A (2013) Lipotoxicity: effects of dietary saturated and trans fatty acids. Mediat Inflamm 2013:13. 10.1155/2013/13757
92. Jaeschke H (2011) Reactive oxygen and mechanisms of inflammatory liver injury: present concepts. J Gastroenterol Hepatol 26:173–179
93. Lyngdoh T, Marques-Vidal P, Paccaud F (2011) Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based colaus study. PLoS One 2011:6
94. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA (2012) Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 55:77–85
95. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J (2007) Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance. World J Gastroenterol 13:4699–4706
96. Zafar U, Qureshi HJ, Imran M (2015) Comparison of iron status and insulin resistance between non-diabetic offspring of type 2 diabetics and non-diabetic offspring of non-diabetics. J Ayub Med Coll 27:307–311
97. Zafar U, Qureshi HJ, Karim S (2011) Insulin resistance and serum parameters of iron status in type 2 diabetics. Pak J Physiol 7:28–31
98. Fernandez-Real JM, Bermejo AL, Ricart W (2002) Cross-talk between iron metabolism and diabetes. Diabetes 51:2348–2354
99. Rishi G, Wallace DF, Subramaniam VN (2015) 2015 Hepcidin: regulation of the master iron regulator. Biosci Rep 35:e00192
100. Ganz T (2011) Hepcidin and iron regulation, 10 years later. Blood 117:4425–4433
101. Ueki K, Kondo T, Tseng YH, Kahn CR (2004) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A 101:10422–10427
102. Martinelli N, Traglia M, Campostrini N, Biino G, Corbella M (2013) Increased serum hepcidin levels in subjects with the metabolic syndrome: a population study. PLoS One 8:10.1371
103. Billiet L, Doaty S, Katz JD, Velasquez MT (2014) Review of hyperuricemia as new marker for metabolic syndrome. JSRN Rheumatol 2014:852954
104. Liu M, He Y, Jiang B (2014) Association between serum uric acid level and metabolic syndrome and its sex difference in a Chinese community elderly population. Int J Endocrinol 2014:754678
105. Sun HL, Pei D, Lue KH, Chen YL (2015) Uric acid levels can predict metabolic syndrome and hypertension in adolescents: a 10-year longitudinal study. PLoS One. 10.1371/journal.pone.0143786
106. Lin S-D, Tsai D-H, Hsu S-R (2006) Association between serum uric acid level and components of the metabolic syndrome. Chin Med J 69:512–516
107. Kanbay M, Jensen T, Solak Y et al (2016) Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med 29:3–8
108. Khosla UM, Zharikov S, Finch JL (2005) Hyperuricemia induces endothelial dysfunction. Kidney Int 67:1739–1742
109. Soltani Z, Rasheed K, Kapusta DR, Reisin E (2013) Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep 15:175–181
110. Emanuela F, Grazia M, de Marco R, Maria Paola L, Giorgio F, Marco B (2012) Inflammation as a link between obesity and metabolic syndrome. J Nutr Metab 2012:476380
111. Stancakova A, Laakso M (2014) Genetics of metabolic syndrome. Rev Endocr Metab Disord 15:243–252
112. Roomi MA, Lone KP, Madassar A (2014) Vitamin D and cardiometabolic risk factors in adult non-diabetic offspring of type 2 diabetic parents. J Pak Med Assoc 64:1229
113. Shahid A, Lone KP, Saeed S, Arslan M (2008) Male offspring of both diabetic parents have higher insulin resistance and serum leptin levels compared to those with one diabetic parent. Hormones 7:313–319
114. Brunetti A (2014) Recent advances in the molecular genetics of type 2 diabetes mellitus. World J Diabetes 5:128–140
115. van Tilburg J, Van Haeften TW, Pearson P, Wijmenga C (2001) Defining the genetic contribution of type 2 diabetes mellitus. J Med Genet 38:569–578
116. Kottyan LC, Woo JG, Keddache M et al (2012) Novel variations in the adiponectin gene (ADIPOQ) may affect distribution of oligomeric complexes. SpringerPlus 1:66
117. Vaxillaire M, Veslot J, Dina C (2008) Impact of common type 2 diabetes risk polymorphisms in the DESIR prospective study. Diabetes 57:244–254
118. Y-y L, Yang Z-j, C-w Z, Wang X-m, Qian Y (2013) Adiponectin-11377CG gene polymorphism and type 2 diabetes mellitus in the Chinese population: a meta-analysis of 6425 subjects. PLoS One 8:e61153
119. Gupta V, Khadgawat R, Tony Ng HK et al (2012) Association of TCF7L2 and ADIPOQ with body mass index, waist-hip ratio, and systolic blood pressure in an endogamous ethnic group of India. Genet Test Mol Biomarkers 16:948–951
120. Chu H, Wang M, Zhong D, Shi D, Ma L, Tong N (2013) AdipoQ polymorphisms are associated with type 2 diabetes mellitus: a meta-analysis study. Diabetes Metab Res Rev 29:532–545
121. Lu JF, Zhou Y, Huang GH, Jiang HX, Hu BL, Qin SY (2014) Association of ADIPOQ polymorphisms with obesity risk: a meta-analysis. Hum Immunol 75:1062–1068
122. Hulkkonen J, Pertovaara M, Antonen J, Pasternack A, Hurme M (2001) Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren’s syndrome and correlate with the clinical manifestations of the disease. Rheumatology 40:656–661
123. Cardellini M, Perego L, D’Adamo M et al (2005) C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. Diabetes Care 28:2007–2012
124. Satti HS, Hussain S, Javed Q (2013) Association of Interleukin-6 gene promoter polymorphism with coronary artery disease in Pakistani families. Sci World J 2013:538365
125. Nadeem A, Mumtaz S, Naveed AK et al (2017) Association of IL-6 C-174G (rs 1800795) single nucleotide polymorphism with type 2 diabetes mellitus in Pakistani population. J Pak Med Assoc 67(428):433
126. Pawlik A, Domanski L, Rozanski J et al (2005) IL-2 and TNF-alpha promoter polymorphisms in patients with acute kidney graft rejection. Transpl Immunol 37:49–52
127. Aoki T, Hirota T, Tamari M, Ichikawa K, Takeda K, Arinami T (2006) An association between asthma and TNF-308G/A polymorphism: meta-analysis. J Hum Genet 51:677–685
128. Zhang LG, Lu H, Lu Y et al (2016) Association between the tumor necrosis factor-α-308G/A polymorphism and COPD susceptibility: a meta-analysis update. Int J Chron Obstruct Pulmon Dis 11:1367–1379
129. Nascimento H, Vieira E, Coimbra S et al (2016) Adipokine gene single-nucleotide polymorphisms in Portuguese obese adolescents: associations with plasma concentrations of adiponectin, resistin, IL-6, IL-1β, and TNF-α. Child Obes 12:300–313
130. Settin A, Abdel-Hady H, El-Baz R et al (2007) Gene polymorphisms of TNF-alpha (-308), IL-10(-1082), IL-6(-174), and IL-1Ra(VNTR) related to susceptibility and severity of rheumatic heart disease. Pediatr Cardiol 28:363–371
131. Babu BM, Reddy BP, Priya VH et al (2012) Cytokine gene polymorphisms in the susceptibility to acute coronary syndrome. Genet Test Mol Biomarkers 16:359–365
132. Takiyama Y, Haneda M (2014) Hypoxia in diabetic kidneys. Biomed Res Int 2014:837421
133. Locatelli F, Fishbane S, Block GA, Macdougall IC (2017) Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol 45:187–199
134. Semenza GL (2014) Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol 76:39–56
135. Yamada N, Horikawa Y, Oda N et al (2005) Genetic variation in the hypoxia-inducible factor-1alpha gene is associated with type 2 diabetes in Japanese. J Clin Endocrinol Metab 90:5841–5847
136. Nagy G, Kovacs-Nagy R, Kereszturi E, Somogyi A, Szekely A, Nemeth N (2009) Association of hypoxia inducible factor-1 alpha gene polymorphism with both type 1 and type 2 diabetes in a Caucasian (Hungarian) sample. BMC Med Genet 10:79
137. Gu HF, Zheng X, Abu Seman N et al (2013) Impact of the hypoxia-inducible factor-1 α (HIF1A) Pro582Ser polymorphism on diabetes nephropathy. Diabetes Care 36:415–421
138. Rankinen T, Sarzynski MA, Ghosh S, Bouchard C (2015) Are there genetic paths common to obesity, cardiovascular disease outcomes, and cardiovascular risk factors? Circ Res 116:909–922
139. Silander K, Scott LJ, Valle TT, Mohlke KL, Stringham HM, Wiles KR (2004) A large set of Finnish affected sibling pair families with type 2 diabetes suggests susceptibility loci on chromosomes 6, 11, and 14. Diabetes 53:821–829
140. Jia Y, Hoang MH, Jun HJ, Lee JH, Lee SJ (2013) Cyanidin, a natural flavonoid, is an agonistic ligand for liver X receptor alpha and beta and reduces cellular lipid accumulation in macrophages and hepatocytes. Bioorg Med Chem Lett 23:4185–4190
141. Watanabe K, Sakurai K, Tsuchiya Y, Yamazoe Y, Yoshinari K (2013) Dual roles of nuclear receptor liver X receptor α (LXRα) in the CYP3A4 expression in human hepatocytes as a positive and negative regulator. Biochem Pharmacol 86:428–436
142. Chen Y, Zhang S, Zhou T, Huang C, McLaughlin A, Chen G (2013) Liver X receptor alpha mediated genistein induction of human dehydroepiandrosterone sulfotransferase (hSULT2A1) in Hep G2 cells. Toxicol Appl Pharmacol 268:106–112
143. Zhao JF, Shyue SK, Lin SJ, Wei J, Lee TS (2014) Excess nitric oxide impairs LXR(α)- ABCA1-dependent cholesterol efflux in macrophage foam cells. J Cell Physiol 229:117–125
144. Wang HX, Zhang K, Zhao L, Tang JW, Gao LY, Wei ZP (2015) Association of liver X receptor α (LXRα) gene polymorphism and ischemic stroke. Genet Mol Res 14:118–122
145. Nohara A, Kawashiri MA, Claudel T, Mizuno M, Tsuchida M, Takata M (2007) High frequency of a retinoid X receptor gamma gene variant in familial combined hyperlipidemia that associates with atherogenic dyslipidemia. Arterioscler Thromb Vasc Biol 27:923–928
146. Pennacchio LA, Rubin EA (2003) Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in human and mice. Arterioscler Thromb Vasc Biol 23:529–534
147. Hubacek JA, Adamkova V, Vrablik M, Kadlecona M, Zicha J, Kunes J (2009) Apolipoprotein A5 in health and diseases. Physiol Res 58:S101–S109
148. O’Brien PJ, Alborn WE, Sloan JH et al (2005) The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 51:351–359
149. Weinberg RB, Cook VR, Beckstead JA et al (2003) Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem 278:34438–34444
150. Zhao T, Zhao J (2010) Association of the apolipoprotein A5 gene–1131 T>C polymorphism with fasting plasma lipids: a meta-analysis in 37859 subjects. BMC Med Genet 11:120
151. Song KW, Cha S, Yu S, Yu H, Oh SA, Kang NS (2013) Association of apolipoprotein A5 gene −1131T>C polymorphism with the risk of metabolic syndrome in Korean subjects. Bio Med Res Int 2013:585134 7 pages
152. Grallert H, Sedlmeier EM, Huth C et al (2007) APOA5 variants and metabolic syndrome in Caucasians. J Lipid Res 48:2614–2621
153. Ursino MG, Vasina V, Raschi E, Crema F, De Ponti F (2009) The B3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res 59:221–234
154. Saliba LF, Reis RS, Brownson RC et al (2014) Obesity-related gene ADRB2, ADRB3 and GHRL polymorphisms and the response to a weight loss diet intervention in adult women. Genet Mol Biol 37:15–22
155. Mirrakhimov AE, Kerimkulova AS, Lunegova OS, Moldokeeva CB, Zalesskaya YV, Abilova SS (2011) An association between TRP64ARG polymorphism of the B3 adrenoreceptor gene and some metabolic disturbances. Cardiovasc Diabetol 10:89
156. Yang H, Cai D, Zhu Q, Wu D, Wang Q, Wang Z (2017) The mutation of Trp64Arg in β3-adrenoreceptor-encoding gene is significantly associated with increased hypertension risk and elevated blood pressure: a meta-analysis. Oncotarget 8:46480–46490
157. Li J, Siegrist J (2012) Physical activity and risk of cardiovascular disease—a meta-analysis of prospective cohort studies. Int J Environ Res Public Health 9:391–407
158. Chaudhury A, Duvoor C, Reddy Dendi VS et al (2017) Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne) 8:6. 10.3389/fendo.2017.00006
159. Nyenwe EA, Jerkins TW, Umpierrez GE et al (2011) Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metab Clin Exp 60:1–23
160. Dawson J, Walters M (2006) Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol 62:633–644
161. Reilly SM, Chiang SH, Decker SJ (2013) An inhibitor of the protein kinases TBK1 and IKK-ε improves obesity-related metabolic dysfunctions in mice. Nat Med 19:313–321
162. Bruce M, Wolfe, Kvach E et al (2016) Treatment of obesity: weight loss and bariatric surgery. Circ Res 118:1844–1855
163. Evers SS, Sandoval DA, Seeley RJ (2016) The physiology and molecular underpinnings of the effects of bariatric surgery on obesity and diabetes. Annu Rev Physiol 79:313–334
164. Kolovou G, Anagnostopoulou K, Cokkinos D (2005) Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 81:358–366